(19)
(11) EP 1 954 258 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
10.10.2012 Bulletin 2012/41

(45) Mention of the grant of the patent:
05.09.2012 Bulletin 2012/36

(21) Application number: 06838553.3

(22) Date of filing: 28.11.2006
(51) International Patent Classification (IPC): 
A61K 31/145(2006.01)
A61P 31/16(2006.01)
 A61P 31/12(2006.01)
(86) International application number:
PCT/US2006/045652
(87) International publication number:
WO 2007/062272 (31.05.2007 Gazette 2007/22)

(54)

MATERIALS AND METHODS FOR TREATING INFLUENZA VIRAL INFECTIONS WITH A CYSTEAMINE COMPOUND

MATERIAL UND VERFAHREN ZUR BEHANDLUNG VON INFLUENZA VIRUSINFEKTIONEN MIT EINER CYSTEAMIN-VERBINDUNG

SUBSTANCES ET METHODES DE TRAITEMENT D'INFECTIONS VIRALES D' INFLUENZA PAR UN COMPOSE DE CYSTEAMINE

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

(30) Priority: 28.11.2005 US 740584 P
02.06.2006 US 810773 P
06.07.2006 US 818885 P
25.09.2006 US 847020 P

(43) Date of publication of application:
13.08.2008 Bulletin 2008/33

(73) Proprietor: OBIO Pharmaceutical (H.K.) Limited
Kowloon, Hong Kong (HK)

(72) Inventors:
  • LIANG, Hao, Yi
    Tianhe, Guangzhou, 510610 (CN)
  • CHI, Francis
    Kowloon, Hong Kong (CN)
  • XU, Qingfu
    Rochester, NY 14620 (US)
  • CHAN, Bill, Piu
    Beijing, 100088 (US)

(74) Representative: Clarke, Lionel Paul 
Gill Jennings & Every LLP The Broadgate Tower 20 Primrose Street
London EC2A 2ES
London EC2A 2ES (GB)


(56) References cited: : 
DE-A1- 19 817 511
 US-A- 5 554 655
   
  • BERGAMINI A ET AL: "IN VITRO INHIBITION OF THE REPLICATION OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 BY BETA-MERCAPTOETHYLAMINE (CYSTEAMINE)" JOURNAL OF INFECTIOUS DISEASES, CHICAGO, IL, US, vol. 174, no. 1, 1996, pages 214-218, XP009033797 ISSN: 0022-1899
  • ANDERSON ROBERT A JR ET AL: "Characterization of cysteamine as a potential contraceptive anti-HIV agent" JOURNAL OF ANDROLOGY, vol. 19, no. 1, January 1998 (1998-01), pages 37-49, XP009079779 ISSN: 0196-3635
  • THOENE J G: "IN VITRO EFFECTIVENESS OF AMINOTHIOLS AND DISULFIDES AGAINST HIV-I" CLINICAL RESEARCH, THOROFARE, NJ, US, vol. 40, no. 2, 1992, page 246A, XP002079347 ISSN: 0009-9279
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).